

Catalogue Number	Product	Order number / Unit
------------------	---------	---------------------

**9830 DOTA-Lanreotide trifluoroacetate**  
**Precursor for radiolabelled DOTA-Lanreotide**  
**Ligand for somatostatin receptors**

**Molar Mass:** 1482.73

$C_{70}H_{95}N_{15}O_{17}S_2$

[213187-44-1] (net peptide)

Colourless to off-white freeze-dried solid packaged in dark glass screw cap vials.

**Purity:**  $\geq 95\%$

**Certificates:**

CoA; MS (identity) and HPLC (purity)

**Chemical Name:**

CA index name: L-Threoninamide, 3-(2-naphthalenyl)-N-[[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-alanyl-L-cysteinyl-L-Tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2→7) disulfide


**Synonymes:**

DOTA-BIM-23014

**Literature:**

1. Smith-Jones P.M. et al. DOTA-Lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. *Endocrinology* 1999, 140, 5136 - 5148.
2. Banerjee S. et al.  $^{177}\text{Lu}$ -DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. *Nucl. Med. Biol.* 2004, 31, 753-759.

**9830.0001: 1 mg per vial**  
**9830.0010: 10 mg per vial**  
**Please inquire for customized filling and bulk quantities.**



DOTA-Lanreotide trifluoroacetate

DOTA- $\alpha$ -2-Nal-Cys-Tyr- $\alpha$ -Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>

date of product catalogue issue: 05 April 2012